Across TCGA pan-cancer cohorts, FGFR3P5 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of FGFR3P5’s most consistent transcriptional readouts.
The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where FGFR3P5 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types FGFR3P5 is over-expressed in tumor.
HNSC and LUSC are the cancer types where FGFR3P5 tumor–normal differential expression is most reproducible.